pretickt

Is GILD a good stock to buy?

Gilead Sciences, Inc. · end-of-day data as of Nov 13, 2026

Gilead
GILD · $208B
$168.08+0.1%
Nov 13, 2026 · close
$160SepOctNov9:3016:003 months +17.8%Nov 13 · close
▲ 4
  • ConsensusBuy · 28
  • Trendbullish
  • MAs4 of 4
  • Sector▲ +15.9%
Neutral
  • Earnings in88d
  • RSI59
  • Support-9.1%
  • Off 52w high-4.8%
  • Volume0.6x
  • Bollingerupper half
  • News0.00
  • 52w range$117–$177
  • ATR+2.7%
  • Off ATH-4.8%
▼ 3
  • PT$165.24 -1.7%
  • Insiders-$39.5M
  • MACD-0.24

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Gilead a good stock to buy?

Gilead is strong on 4 of the 5 questions about the business. With a loss over the last 12 months, Gilead has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage hard to copy
  3. Economics profits growing
  4. Execution delivers
  5. Fragility sturdy
  6. Price above its peers
DemandDo people want more of what it sells?steady

GILD sales growth revenue growth

+3%a year, for the last 3 years

Gilead's sales grew 3% a year for 3 years, to $29.44B in fiscal 2025.

GILD analysts' forecast revenue estimates

+6%the sales they expect next fiscal year, on the last

Analysts expect Gilead's sales to grow 6% to $31.27B in fiscal 2026 (17 analysts).

GILD competitors

pretickt analysis+7%its sales in 12 months, on a year before

Gilead's sales grew 7% in the 12 months to Sep 30, 2026, faster than Merck (+5%), Bristol-Myers Squibb (+4%) and Pfizer (+1%), slower than Amgen (+8%).

GILD customers' spending

pretickt analysis+23%what its customers invest, on a year before

Cencora, Cardinal Health and McKesson, customers of Gilead, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.

GILD sales by business revenue by segment

49%of its sales from Biktarvy

Biktarvy brought Gilead 49% of its sales in fiscal 2025; Descovy 9%.

Advantage moatIs it hard to copy?hard to copy

GILD margin on each sale gross margin

80%left after making the product

Gilead kept 80% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 74%.

EconomicsDoes it make good money?profits growing

GILD profit per share

+1,730%in its last fiscal year

Gilead's earnings per share grew 1,730% in fiscal 2025, to $6.77.

ExecutionDoes it deliver what it promises?delivers

GILD earnings vs estimates

8 of 8quarters above the analysts' estimate

Gilead beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 29, 2026.

GILD insider selling

-$106Msold, net, by its executives in 12 months

Gilead's executives and directors sold a net $106M of shares in the 12 months to Nov 13, 2026; none bought.

GILD number of employees

-3%fewer people in a year

Gilead had 17,000 employees at the end of fiscal 2025, 3% fewer than a year before.

GILD CEO pay

$28.44Mfor fiscal 2025, 69% of it in stock and options

Gilead paid its CEO $28.44M for fiscal 2025, 69% of it in stock and options.

Fragility risksCould something break it?sturdy

GILD financial health Altman Z-score

3.9Altman Z-score, safe above 3

Gilead's Altman Z-score is 3.9 (Nov 13, 2026), above 3, where the safe zone starts.

GILD biggest customers

74%of sales from its 3 biggest customers

CAH, COR and MCK made 74% of Gilead's sales in fiscal 2025.

GILD shareholders institutional ownership

pretickt analysis
  • BlackRock9.8% ▲
  • Vanguard9.4% ▲
  • Fidelity5.4% ▼
2,377institutions hold it; the largest added shares

2,377 institutions hold 90% of Gilead's shares (Jun 30, 2026); BlackRock and Vanguard added shares that quarter, Fidelity sold some.

GILD in past recessions

pretickt analysis+10%its sales in the worst one

Gilead's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?above its peers

GILD price vs profit P/E ratio

—it lost money in 12 months: no P/E

Gilead has no P/E ratio: it lost money over the 12 months to Sep 30, 2026.

GILD price vs assets price to book

16.0×times what its assets are worth on paper

Gilead trades at 16.0 times its book value (Nov 13, 2026); its competitors' median is 6.8.

GILD analysts' target price target

-2%to their average target

Analysts' average price target for Gilead is $165, 2% below the Nov 13, 2026 close of $168.08.

What is Gilead's P/E ratio?

Gilead has no P/E ratio: it lost money over the 12 months to Sep 30, 2026. Gilead trades at 16.0 times its book value (Nov 13, 2026); its competitors' median is 6.8.

Who are Gilead's biggest competitors?

pretickt compares Gilead with Amgen, Pfizer, Bristol-Myers Squibb and Merck. Gilead's sales grew 7% in the 12 months to Sep 30, 2026, faster than Merck (+5%), Bristol-Myers Squibb (+4%) and Pfizer (+1%), slower than Amgen (+8%).

Are insiders selling Gilead stock?

Gilead's executives and directors sold a net $106M of shares in the 12 months to Nov 13, 2026; none bought.

How does Gilead make money?

Biktarvy brought Gilead 49% of its sales in fiscal 2025; Descovy 9%.

Who owns Gilead stock?

2,377 institutions hold 90% of Gilead's shares (Jun 30, 2026); BlackRock and Vanguard added shares that quarter, Fidelity sold some.

How many employees does Gilead have?

Gilead had 17,000 employees at the end of fiscal 2025, 3% fewer than a year before.

Who are Gilead's biggest customers?

CAH, COR and MCK made 74% of Gilead's sales in fiscal 2025. Cencora, Cardinal Health and McKesson, customers of Gilead, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.